Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: RTX stock price vs MRK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRK's multiple
Needs MRK P/E.
Implied fair value · at RTX's multiple
Needs RTX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
RTX CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Merck & Co., Inc. · implied price per share
Bear
$49.07
Base
$60.10
Bull
$74.45
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
General Electric Company
RTX vs GE
HONEYWELL INTERNATIONAL INC
RTX vs HON
Parker-Hannifin Corp
RTX vs PH
Spirit AeroSystems Holdings, Inc.
RTX vs SPR
TransDigm Group INC
RTX vs TDG
Pfizer Inc.
RTX vs PFE
Johnson & Johnson
RTX vs JNJ
Eli Lilly and Company
RTX vs LLY
Bristol-Myers Squibb Company
RTX vs BMY
AbbVie Inc.
RTX vs ABBV
AMGEN INC
RTX vs AMGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe RTX can sustain 9.7% revenue growth while materially improving margins toward MRK levels, then hold or buy on weakness because the current discount implied by DCF and P/E may prove too punitive; otherwise, trim or avoid because RTX is priced well above the valuation implied by its weaker profitability.
RTX trades at a significant premium to MRK on earnings-based valuation despite weaker margins and lower net profitability. The implied price of $88.71 is 58.8% below the current price of $215.22, while MRK-implied range and DCF range both sit far below the market price.
Supporting Metrics
